News | Musculoskeletal conditions

News

No evidence vitamin D supplements improve bone health, major analysis finds

Vitamin D supplements for adults do not prevent fractures, falls or improve bone mineral density, according to authors of the biggest review of evidence to date.…

Published: 8 October 2018

News

Alendronate may lower cardiovascular risk in hip fracture patients

Study finds a treatment for osteoporosis may reduce the risk of cardiovascular events in people with hip fractures.…

Published: 4 July 2018

Opinion

Help us understand your experience of supporting patients with osteoarthritis

The Pharmaceutical Journal launches insight-led campaign to advance pharmacy’s role in management of osteoarthritis.…

Published: 8 June 2018

News

Halting TNF-inhibitors in rheumatoid arthritis patients in remission could lead to significant savings, research reveals

Stopping tumour necrosis factor inhibitors in rheumatoid arthritis patients who are in remission or have low disease activity was associated with savings of more than €7,000.…

Published: 17 May 2018

News

Rheumatoid arthritis drug may reduce inflammation after stroke

The pro-inflammatory cytokine interleukin-1 plays a significant role in brain injury following ischemic stroke by inducing peripheral inflammatory mediators, such as interleukin-6. However, pre-clinical studies show its effects are reduced by the interleukin-1 receptor antagonist.…

Published: 14 May 2018

News

Study results do not support use of hydroxychloroquine in hand osteoarthritis

There is anecdotal evidence that the slow-acting anti-inflammatory treatment hydroxychloroquine, used to treat rheumatoid arthritis, could also be effective in osteoarthritis. …

Published: 6 April 2018

News

Researchers develop NO-responsive hydrogel that could be used in rheumatoid arthritis

Researchers explored the development of a polymer hydrogel that rapidly swells in response to nitric oxide that could be implanted into joints in rheumatoid arthritis.…

Published: 2 January 2018

News

Adalimumab biosimilar exhibits same efficacy and safety for rheumatoid arthritis as originator

Patients with rheumatoid arthritis who switched from adalimumab (Humira) to its biosimilar, adalimumab-adbm (Cyltezo), saw no clinically meaningful difference, according to the results of a 48-week Phase III clinical trial…

Published: 10 November 2017

News

Ibuprofen raises blood pressure more than celecoxib

Study investigated the link between non-steroidal anti-inflammatory drugs and raised blood pressure and heart problems in patients who either had, or were at increased risk, of coronary artery disease. …

Published: 5 October 2017

News

Romosozumab reduces fracture risk in postmenopausal women with osteoporosis

Researchers find that the drug can be an effective treatment for women who are susceptible to fracture.…

Published: 14 September 2017